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A bstract
Background: A  polymorphism at codon 129 o f the prion protein gene (PRNP) is the only well- 
known genetic risk factor fo r Creutzfeldt-Jakob disease (CJD). However, there is increasing 
evidence that other loci outside the PRNP open reading frame might play a role in CJD aetiology as 
well.
Methods: W e studied tau protein gene (MAPT) haplotypic variations in a population of sporadic 
and variant CJD patients. W e tested 6 MAPT haplotype tagging SNPs (htSNPs) in a Dutch 
population-based sample o f sporadic CJD (sCJD) patients and a cognitively normal contro l group 
of similar age distribution. W e genotyped the same polymorphisms in tw o  other sample groups of 
sCJD cases from  Italy and the UK. In addition, we compared MAPT haplotypes between sCJD and 
variant CJD (vCJD) patients.
Results: Single locus and haplotype analyses did not detect any significant difference between sCJD 
cases and controls. W hen we compared MAPT haplotypes between sCJD and variant CJD (vCJD) 
patients, we found that tw o of them were represented differently (H1f: 8% in sCJD versus 2% in 
vCJD; H1j:1% in sCJD versus 7% in vCJD). However, these tw o  haplotypes were rare in both 
groups of patients, and taking the small sample sizes into account, we cannot exclude that the 
differences are due to  chance. None of the p-values remained statistically significant after applying 
a multiple testing correction.
Conclusion: O ur study shows no evidence fo r an association between MAPT gene variations and 
sCJD, and some weak evidence fo r an association to  vCJD.
Open Access
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Background
Tau protein plays a key role in  the pathogenesis of several 
neurodegenerative disorders. Neurofibrillary tangles 
(NFTs) consisting of accum ulation of truncated and 
hyperphosphorylated tau are one of the hallm arks of 
Alzheimer's disease (AD) [1]. NFTs are also present in 
other neurodegenerative diseases, including progressive 
supranuclear palsy (PSP), cortico basal degeneration 
(CBD), Pick's disease, and  argyrophilic grain disease and 
Parkinson's disease (PD) [1-4]. In patients w ith sporadic 
CJD, the tau protein is profusely released to the CSF [5]. 
This process is m ost likely related to the rapid neuronal 
damage. Tau quantification w ith Enzyme Linked Im m u­
nosorbent Assay (ELISA) is a very valuable aid for sCJD 
diagnosis [6]. In contrast to sCJD, in  vCJD there is an 
increase of phosphorylated-tau forms in  CSF [7]. The 
pathogenic im plications of this finding are unknow n, bu t 
it suggests tha t tau phosphorylation may differ between 
sCJD and  vCJD.
lance network EuroCJD [23]. Only patients o f Caucasian 
origin w ho fulfilled the W HO diagnostic criteria for defi­
nite or probable CJD were included [24]. Definite CJD 
diagnosis was based on neuropathological exam ination. 
Probable cases required an  appropriate clinical profile, 
supported by characteristic findings on MRI, EEG or CSF 
14-3-3-protein detection. W henever possible, all EEGs 
and  MRIs were reviewed by a m em ber of the surveillance 
system and  scored for the presence or absence of typical or 
characteristic diagnostic features [25,26]. The CSF 14-3-3 
im m unoassays were perform ed using W estern-blotting 
[27]. Healthy controls (n = 309) were participants of the 
Rotterdam  Study, w hich is a population-based study of 
7385 subjects aged 55 years or older [28]. Controls are all 
cognitively norm al and from  Caucasian origin. Signed 
inform ed consent to  participate in  genetic research, 
approved by the Medical Ethics Com m ittee of the Eras­
m us Medical Center, was obtained from  all controls and 
patients relatives.
The tau protein is encoded by MAPT gene, located in  chro­
m osom e 17. M utations in  MAPT have been identified in 
frontotem poral dem entia (FTD) and  pallidopontonigral 
degeneration [8-13]. There are two com m on MAPT 
extended haplotypes in  Caucasians, H1 and  H2. The H1 
haplotype has been linked to several sporadic neurode­
generative disorders like PSP [14-16], CBD [17], FTD [18], 
Parkinson's [19] and som e studies suggest to  Alzheimer's 
disease [20].
A recent study using data from  the HapM ap project [21] 
identified 6 htSNPs capturing 95% o f MAPT genetic vari­
ability in  Caucasians [22]. The same group showed that 
H1c, one of the H1 subhaplotypes, was linked to  late 
onset AD [20]. In the present study we exam ined the asso­
ciation between MAPT haplotypic variants and  risk of 
sCJD and  vCJD.
Methods
Cases were derived from  population-based surveys of CJD 
carried ou t by national CJD registries from  1991 to  2005 
in  Italy (n = 194 sCJD), the United Kingdom (UK) (n = 48 
sCJD and  52 vCJD) and the N etherlands (n = 79 sCJD). 
All three countries are part of the European CJD surveil­
For all patients and controls, DNA has been extracted 
from  peripheral leucocytes according to  a standard p ro to­
col. We genotyped five polym orphism s, w hich had been 
previously show n to tag the haplotype diversity of MAPT 
in  Caucasians (Figure 1) [22]. Additionally, the H1/H 2 
clade was defined by typing the SNP g.8117G>A [num ber­
ing according to  GenBank accession num ber 
AC091628.2], w ith the allele G tagging H1, and  the allele 
A tagging H2 [29]. DNA samples were genotyped w ith a 
TaqMan allelic discrim ination assay by using the primers 
show n in Table 1.
Hardy-W einberg equilibrium  (HWE) was calculated for 
the 6 htSNPs genotypes in  the control population  using x 2 
statistics. We set a significance level o f 0.01 in  order to 
take in to  account the num ber o f tests performed. We 
assessed pairwise linkage disequilibrium  (LD) between 
the 6 htSNPs using D' and r2 calculated from  the expecta- 
tion-m axim ization estim ated haplotypes (Figure 2). We 
used the program  SNPStats [30] for the LD analysis. Single 
locus analyses were perform ed using SPSS software ver­
sion 13. Allelic and  genotypic frequencies were com pared 
using x2 statistics. Adjusted analyses were perform ed using 
m ultiple logistic regression analysis. Age, gender and
Figure 1
Scheme of MAPT genomic structure showing the position o f the 6 SNPs genotyped.
Page 2 of 8
(page number not for citation purposes)
BMC Medical Genetics 2007, 8:77 
T a b le  1 : S N P  sequence
http://www.biomedcentral.com/1471-2350/B/77
S N P P r im e r  sequence
Rs242559 A G A A A G T T C T C C C A G G A A A C A A G A G
A T T C C T T A G C T G T T A C C A G T C A C T G
Rs242557 C G TT T C T T C T T C C T T A C A A A G C A G T T  
TG TC A C G G G A C C A G G G
Rs3785883 G C TC A G C G A T A T T G T C A C A T G A C  
A G TG T C G G C TG G A T G G A C
Rs2471738 A G TG G C C T G G TT A G A G A C C TT
TC T G TC C TG TA C C G C A G C
H1/H2 G C C G TC C G C C TC T G T
C A TC G G T C G G G G C C A
Rs7521 C C T G C G T G TC C C A TC TA C A G
T C T T C A G C T T T G A A A A G G G T T A C C C
PRNP M129V genotype were included in  the m odel as 
covariates. We first com pared Dutch sCJD cases and con­
trols using the Italian and UK sCJD populations as repli­
cation samples. In a separate analysis we com pared UK 
sCJD w ith vCJD. Haplotype analyses were performed 
using the program  hplus [31]. We perform ed haplotype 
analysis com paring controls versus all sCJD patients and 
UK sCJD patients w ith vCJD patients.
Results
Table 2 shows the basic characteristics of our patients and 
controls. All htSNPs were in  HWE (p > 0.01). Allele fre­
quencies in  our control sam ples were com parable to  pre­
vious published data [20].
In the first analysis we tested w hether MAPT genetic vari­
ations were associated w ith risk of sCJD. N one of the 
htSNPs genotypes showed a statistically significant associ­
ation w ith the disease w hen com paring the Dutch cases to 
the m atched controls nor w hen com paring the other n o n ­
D utch patients. Also the pooled analysis was no t signifi­
cant. Adjustm ent for age, gender and PRNP M129V geno­
type did no t alter this conclusion. W hen we com pared in 
a separate analysis MAPT genetic variants between UK 
sCJD and  vCJD, we also failed to  find any statistically sig­
nificant association (Table 3).
The htSNPs genotyped allowed us to  define the two m ajor 
clades, H1 and H2, which have been described in  Cauca­
sians in  several previous studies [32]. In order to  facilitate 
com parisons we have adopted the sam e term inology for 
H1 sub-haplotypes as tha t used by Pittm an et al. [22]. We
did no t find any evidence of association between any of 
the MAPT haplotypes and  sCJD. We specifically did no t 
find association w ith the subhaplotype H1c, w hich has 
been previously reported to  be related to several neurode­
generative diseases. We also com pared MAPT haplotypes 
between sCJD and vCJD from  the UK. We found that the 
frequency o f two rare haplotypes, H 1f and  H1j, were sig­
nificantly different in  sCJD (p = 0.04) and  vCJD patients 
(p = 0.01) (Table 4). However, these two variants were 
present in  a small proportion  of patients, and  after adjust­
ing by the num ber of test perform ed (14 pairwise haplo- 
typic com parisons were made) the results were no t 
statistically significant (p = 0.5G for H1f) and (p = 0.14 for 
H1j). W hen we com pared the frequency of these hap lo ­
types in  vCJD versus the Dutch control population, only 
the difference in  H1j (3% in controls versus 7% in vCJD) 
was of borderline significance (p = 0.0G).
Discussion
O ur study assesses the relationship between MAPT haplo- 
typic variations and  CJD for the first time. To the best of 
our knowledge, there has only been one published article 
studying the role of MAPT in  sCJD aetiology [33]. 
Sánchez-Valle et al. found no association between a poly­
m orphism  in exon 1 of MAPT in  a group of 29 sCJD cases 
and  29 controls. We exam ined G htSNPs, w hich are part of 
an  extended MAPT haplotype, in  a D utch population- 
based sam ple of sCJD patients and  a cognitively norm al 
control group o f sim ilar age distribution. Statistical analy­
sis revealed no significant differences between cases and 
controls, w ith all p-values higher than  0.05 before correct­
ing for m ultiple testing. Haplotype analysis still failed to
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Figure 2
Linkage disequilibrium (LD) p lot showing pairwise correlation between SNPs.
detect any significant difference. We genotyped the same 
polym orphism s in  two other sam ple groups of sCJD cases 
from  Italy and the UK. All three populations of cases 
showed sim ilar dem ographical characteristics. D ue to 
selection bias in  the low  num ber of UK sCJD cases tested 
(n = 48), valine carriers were overrepresented in  this sub­
group. The frequencies o f codon 129 genotypes in  UK 
sCJD cases are sim ilar to  those found in  other European
countries. O ur data do not show  association between 
PRNP codon 129 and any o f the MAPT SNPs. Therefore 
our conclusion o f no association between MAPT and sCJD 
is not affected by the differences in  PRNP genotypic distri­
bu tion  in  the sam ple sets.
In  our single locus analysis we did not find any significant 
difference between UK sCJD and vCJD patients. We found
T a b le  2: D e s c r ip tiv e  s ta t is t ic s
O r ig in S e ries n % F e m a les % D e f in ite M e d ia n  age P R N P  M 1 2 9 V  g e n o ty p e
d ia g n o s is (ra n g e )
M M  n (%) M V  n (%) V V  n (%)
NL sCJD 79 59 52 67 (34-87) 48 (67) 16 (22) 8 (11)
contro ls 309 56 N /A 71 (55-93) 135 (45) 145 (48) 23 (8)
UK sCJD 48 58 50 67 (49-81) 22 (46) 13 (27) 13 (27)
vCJD 52 31 74 25 (12-62) 52 (100) 0 (0) 0 (0)
Italy sCJD 194 57 73 67 (35-87) 141 (73) 31 (16) 22 (11)
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S N P  (a lle les )
rs242559 (A/c) rs242557 (G/a) rs3785883 (G / rs2471738 (C /t) H1/H2 (G/a)
a)
rs7521 (G/a)
C o n t ro ls
Major allele 
count 
(frequences)
Genotype
distribution
(frequences)
w t
w t-v
v-v
467 (0.76)
180 (0.60) 
107 (0.29)
19 (0.11)
382 (0.63)
123 (0.40) 
136 (0 .45)
46 (0.15)
501 (0.82)
205 (0.67) 
91 0.30)
10 (0.03)
495 (0.81)
208 (0.68) 
79 (0.26)
18 (0.06)
469 (0.77)
183 (0.60) 
103 (0 .34)
18 (0.06)
330 (0.54)
91 (0.30) 
148 (0.48)
67 (0.22)
N L  sCJD
Major allele 116 (0.73) 95 (0.60) 134 (0.85) 124 (0.78) 115 (0.73) 88 (0.56)
count
(frequences)
w t 47 (0.60) 29 (0.37) 56 (0.71) 50 (0.64) 47 (0.62) 27 (0.35)
Genotype w t-v 22 (0.28) 37 (0.48) 22 (0.28) 24 (0 .31) 21 (0.28) 34 (0.43)
distribution
(frequences)
v-v 9 (0.12) 12 (0.15) 1 (0.01) 4 0.05) 8 (0.10) 17 (0.22)
P-values Allelic 0.6 0.71 0.41 0.65 0.75 0.59
Genotypic 0.19 [0.32] 0.87 [0.70] 0.58 [0.76] 0.68 [0.66] 0.27 [0.45] 0.68 [0.71]
I ta ly  sCJD
Major allele 297 (0.76) 248 (0.64) 319 (0.82) 301 (0.78) 300 (0.77) 205 (0.53)
count
(frequences)
w t 111 (0.58) 84 (0.44) 133 (0.70) 122 (0.64) 116 (0.62) 54 (0.28)
Genotype w t-v 75 (0.39) 80 (0.42) 51 (0.28) 57 (0.30) 68 (0.36) 97 (0.51)
distribution
(frequences)
v-v 6 (0.03) 28 (0.14) 5 (0.02) 12 (0.06) 4 (0.02) 40 (0.21)
P-values A lle lic 0.76 0.54 0.55 0.37 0.34 0.95
Genotypic 0.25 [0.43] 0.75 [0.73] 0.80 [0.20] 0.60 [0.77] 0.14 [0.54] 0.87 [0.78]
U K  sCJD
Major allele 69 (0.72) 65 (0.68) 82 (0.85) 71 (0.74) 69 (0.72) 59 (0.61)
count
(frequences)
Genotype w t 25 (0.52) 22 (0.46) 36 (0.75) 28 (0.58) 25 (0.52) 20 (0.42)
distribution
(frequences)
w t-v 19 (0.40) 21 0.44) 10 (0.21) 15 (0.31) 19 (0.40) 19 (0.39)
v-v 4 (0.08) 5 (0.10) 2 (0.04) 5 (0.11) 4 (0.08) 9 (0.19)
P-values A lle lic 0.37 0.36 0.47 0.13 0.3 0.19
Genotypic 0.65 [0.42] 0.63 [0.47] 0.44 [0.17] 0.31 [0.62] 0.54 [0.31] 0.25 [0.15]
O v e ra ll sCJD
Major allele 482 (0.76) 408 (0.64) 535 (0.84) 496 (0.78) 484 (0.78) 352 (0.56)
count
(frequences)
w t 183 (0.58) 135 (0.43) 225 (0.71) 200 (0.63) 188 (0.60) 101 (0.32)
Genotype w t-v 116 (0.36) 138 (0 .43) 85 (0.27) 96 (0.30) 108 (0 .35) 150 (0 .47)
distribution
(frequences)
v-v 19 (0.06) 45 (0.14) 8 (0.02) 21 (0.07) 16 (0.05) 66 (0.21)
P-values Allelic 0.84 0.6 0.29 0.2 0.89 0.61
Genotypic 0.92 [0.73] 0.85 [0.66] 0.57 [0.36] 0.46 [0.58] 0.90 [0.87] 0.84 [0.77]
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T a b le  3: S ing le  locus analysis o f  th e  asso c ia tion  b e tw e e n  M A P T  and  C re u tz fe ld t-J a k o b  disease (Continued)
U K  vC JD
Major allele 67 (0.66) 64 (0.63) 90 (0.87) 80 (0.78) 67 (0.67) 61 (0.60)
count
(frequences)
w t 21 (0.41) 19 (0.37) 39 (0.75) 31 (0.61) 23 (0.46) 19 (0.37)
Genotype w t-v 25 (0 .49 ) 26 (0 .51) 12 (0.23) 18 (0 .35) 21 (0.42) 23 (0.45)
distribution
(frequences)
v-v 5 (0.10) 6 (0.12) 1 (0.02) 2 (0.04) 6 (0.12) 9 (0.18)
P-values A lle lic 0.36 0.55 0.84 0.51 0.54 0.88
Genotypic 0.28 [0.26] 0.39 [0.79] 0.99 [0.96] 0.80 [0.60] 0.55 [0.27] 0.65 [0.99]
P-values are no t corrected fo r multip le testing
In brackets p-values adjusted by PRNP M129V genotype, age at onset and gender 
w t: w ild type 
v: variant
sCJD: sporadic C reu tzfe ldt Jakob disease 
vCJD:variant C reu tzfe ldt Jakob disease
som e MAPT  haplotype frequencies unequally distributed, 
but none of the differences rem ained statistically signifi­
cant after applying a m ultiple testing correction.
O ne possible caveat of our study is the fact that we 
included a proportion of clinically diagnosed cases (26% 
vCJD and 36% sCJD). However, it has been show n that 
"probable" cases fulfilling the clinical diagnostic criteria 
have a very high positive predictive value (98.5%) [34].
Lack of statistical power could be another explanation for 
our results. We th ink  that this is unlikely. As a proof of 
principle, the association of sCJD w ith PRNP M129V gen­
otypes in  the overall sam ple yielded a very low p-value
(<10-11). The sCJD risk of PRNP 129 M hom ozygotes ver­
sus PRNP 129 heterozygotes was 3.8 folds higher (95%CI 
from  2.6 to  5.5). W ithout m ultiple testing corrections we 
estim ated that the statistical power of our genotypic anal­
ysis w ould be o f 85% to detect an  odds ratio as low as 1.6. 
In order to  increase the power of the study, we pooled all 
sCJD cases. Therefore, although they were all Caucasians, 
in  the second stage o f the analysis not all sCJD cases and 
controls came from  the same country. Another caveat of 
the study is the fact that the com parison between UK spo­
radic versus variant CJD was no t age-matched. However, 
to  the best o f our knowledge, there are not MAPT age- 
related variations and, therefore, this should not be a 
m ajor issue for our analysis.
T a b le  4: H a p lo ty p e  analysis o f  th e  asso c ia tion  b e tw e e n  M A P T  and  C re u tz fe ld t-J a k o b  disease 
H a p lo t  A lle le s  F re q u e n c y  P -va lue  F re q u e n c y  P -va lue
y p e
rs2 4255  rs2 4255  rs3 7 8 5 8  rs2 4717  H 1 /H 2  rs7521 C o n t ro l sCJD U K  U K
9 7 83 38 s sCJD vC JD
H1e A G G C G A 0.25 0.26 ref 0.24 0.2 0.51
H2a C G G C A G 0.23 0.22 0.64 0.28 0.31 ref
H1c A A G T G G 0.12 0.15 0.46 0.16 0.1 0.4
H1d A A G C G A 0.13 0.1 0.08 0.07 0.16 0.18
H1f A G A C G G 0.05 0.05 0.88 0.08 0.02 0.04
H1g A A G C G G 0.05 0.05 0.91
H1h A G A C G A 0.04 0.04 0.64
H1i A A A C G A 0.03 0.03 0.68
H1j A A A T G G 0.03 0.02 0.45 0.01 0.07 0.01
H1b A G G C G G 0.02 0.02 0.55
P-values are no t corrected fo r multip le testing 
Included all haplotypes present in both sCJD and vCJD 
sCJD: sporadic C reu tzfe ldt Jakob disease 
vCJD:variant C reu tzfe ldt Jakob disease
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Conclusion
O ur study shows no evidence for an association between 
MAPT gene variations and  sCJD, and  som e weak evidence 
for an association to  vCJD.
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